Short Review

Induced dopaminergic neurons: A new promise for Parkinson’s disease

Zhimin Xu\textsuperscript{a,b,c}, Xingkun Chue, Houbo Jiang\textsuperscript{a,b}, Haley Schilling\textsuperscript{b}, Shengdi Chen\textsuperscript{c}, Jian Feng\textsuperscript{a,b,*}

\textsuperscript{a} Veterans Affairs Western New York Healthcare System, Buffalo, NY 14215, USA
\textsuperscript{b} Department of Physiology and Biophysics, State University of New York at Buffalo, Buffalo, NY 14214, USA
\textsuperscript{c} Laboratory of Neurodegenerative Diseases, Institute of Health Science, Shanghai Institutes for Biological Sciences, Chinese Academy of Science and Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

\textbf{A R T I C L E  I N F O}

Keywords:
Parkinson’s disease
Induced dopaminergic neuron
Induced neuron
Induced pluripotent stem cell
Transcription factor

\textbf{A B S T R A C T}

Motor symptoms that define Parkinson’s disease (PD) are caused by the selective loss of nigral dopaminergic (DA) neurons. Cell replacement therapy for PD has been focused on midbrain DA neurons derived from human fetal mesencephalic tissue, human embryonic stem cells (hESC) or human induced pluripotent stem cells (iPSC). Recent development in the direct conversion of human fibroblasts to induced dopaminergic (iDA) neurons offers new opportunities for transplantation study and disease modeling in PD. The iDA neurons are generated directly from human fibroblasts in a short period of time, bypassing lengthy differentiation process from human pluripotent stem cells and the concern for potentially tumorigenic mitotic cells. They exhibit functional dopaminergic neurotransmission and relieve locomotor symptoms in animal models of Parkinson’s disease. In this review, we will discuss this recent development and its implications to Parkinson’s disease research and therapy.

1. Introduction

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, after Alzheimer’s disease. PD is characterized by its hallmark motor symptoms such as resting tremor, rigidity, bradykinesia and postural instability [1]. A variety of non-motor symptoms (NMSs), including dementia, depression, sensory dysfunction, dysautonomia, sleep disturbances, etc. are frequently comorbid with and sometimes precede the motor symptoms [1]. The pathology that defines PD, which is also the cause of its motor symptoms, is a rather selective and progressive loss of nigrostriatal dopaminergic (DA) neurons, while NMSs may result from degeneration of non-dopaminergic (e.g. serotonergic, noradrenergic and cholinergic) neurons in other parts of the brain [2]. Over 90% of PD cases are idiopathic, without a clear etiology. Extensive research on monogenic forms of Parkinson’s disease has shed significant insights into the molecular and cellular events that underlie the selective loss of nigral DA neurons in PD [3]. Current treatments for PD, including medication (e.g. levodopa, dopamine agonists, MAO-B inhibitors or COMT inhibitors) and surgery (e.g. deep brain stimulation of globus pallidus or subthalamic nucleus), only relieve symptoms and cannot significantly change disease progression [2]. A disease-modifying therapy for PD is long sought-after and will fundamentally change the care of PD patients.

Decades of research on the transplantation of DA neurons have demonstrated that human fetal ventral mesencephalic cells grafted in striatum can provide very long-term benefits (more than 15 years and ongoing) in a small number of patients so that they function independently without PD drugs [4,5], although many factors contribute to the lack of therapeutic benefits in most patients [6]. Recent studies show that midbrain DA neurons differentiated from human ES cells with the floorplate-based method perform as well as human fetal ventral mesencephalic cells in 6-OHDA-lesioned rat model of Parkinson’s disease [7]. One main concern for the use of stem cell-derived dopamine neurons is the potential presence of mitotic cells, which may give rise to tumors after transplantation. The recent development of induced dopaminergic (iDA) neurons, which are directly converted from human fibroblasts [8,9], may provide a useful alternative to stem cell-derived dopamine neurons in cell replacement therapy for PD. In this review, we will highlight the conversion methods, as well as the functional characteristics and utility of induced dopaminergic neurons in PD research and therapy (Fig. 1).

2. Direct conversion of fibroblasts to induced neurons

In 2010, Marius Wernig and colleagues made a significant breakthrough with the identification of transcription factors [Bra2, Ascl1 and Myt1l (BAM)] that directly convert mouse embryonic fibroblasts (MEFs) to induced neurons (iN) [10]. This method does not involve...
stem cells; the reprogramming of fibroblasts with BAM leads to rapid cell cycle exit within 24 h of turning on reprogramming factors [10]. The direct conversion takes about two weeks to generate induced neurons. This method has been successfully extended to the human system, where fetal and postnatal human fibroblasts are converted to iN with BAM plus NeuroD1 [11]. Many groups have successfully converted mouse, porcine, non-human primate [12] or human fibroblasts into iN, DA neuronal progenitors (iDPs) [13,14], dopaminergic neurons [8,15,16], motor neurons (hiMNs) [17–19], peripheral sensory neurons [20], striatal medium spiny neurons (MSNs) [21,22], cholinergic neurons [23], serotonergic neurons [24,25], GABAergic neurons [26], glutamatergic neurons [27], neural precursor cells [28] and oligodendrocyte progenitor cells [29,30], with different combinations of transcription factors and media additives (small molecule compounds and growth factors).

3. Direct conversion of fibroblasts to induced dopaminergic neurons

As shown in Table 1, many groups independently identify various transcription factor combinations that can be used to convert fibroblasts to induced dopaminergic (iDA) neurons [8,9,15,16,31–35]. This is accomplished by overexpression of transcription factors involved in the specification of dopaminergic neurons during development, together with a combination of small molecule compounds and neurotrophic factors to facilitate the survival and maturation of converted iDA neurons. Despite the differences in reprogramming factors and various other conditions used, the iDA neurons that are converted from fibroblasts share many similar properties. For example, they all express neuronal markers such as β3-tubulin, MAP2 and NeuN, as well as the dopaminergic markers TH, AADC, VMAT2, ALDH1A1, Nurr1, Pitx3, DAT, midbrain markers such as FoxA2 and En1, and synaptic markers such as PSD95 and Syntaxin1. In addition, qRT-PCR and RNAseq analysis of iDA neurons confirmed the enriched expression of dopaminergic genes, such as TH, Vmat2, AADC, Ret, Gfra1, Foxa1, GDNF, Drd2 and synaptic markers such as synaptotagmin I and synapsins.

Dopamine release and reuptake are observed in iDA neurons. They exhibit electrophysiological activities such as action potentials and excitatory postsynaptic currents. Finally, transplantation of iDA neurons generated from MEF cells in 6-OHDA-lesioned mice alleviated motor deficits [16].

4. Many different types of cells can be converted to induced neurons in vitro and in vivo

The discovery of the transdifferentiation of fibroblasts to induced neurons stimulates a plethora of studies on the conversion of various cell types to neurons. As summarized in Table 2, a diverse array of cell types have been used in the conversion experiments, with different combinations of transcription factors and media additives, yielding a variety of induced neurons at varying efficiency. For example, astrocytes can be converted to neurons using a single transcription factor such as Neurog2, Brn4, NeuroD1, Ascl1 or Dlx2 in vitro and in vivo [36–40]. Sox2 alone can reprogram astrocytes and NG2+ glia cells to

**Table 1** Summary of iDA neurons directly converted from fibroblasts.

| Source Cells | Transcription factors | Media | Efficiency (%) | Time (days) | Ref. |
|--------------|-----------------------|-------|----------------|------------|------|
| HEF; HPF    | Ascl1, Brn2, Myt11, Foxa2, Lmx1a | insulin, transferrin, sodium selenite, progesterone, putrescine | 1.6; 0.4 | 20–24 | [15] |
| MEF; IMR90; HAF | Ascl1, Nurr1, Lmx1a | insulin, transferrin, sodium selenite, progesterone, putrescine | 18; 6 | 6–16 | [8] |
| TTFs        | Ascl1, Nurr1, Lmx1a, Pitx3, Foxa2, En1 | insulin, transferrin, sodium selenite, progesterone, putrescine, FGF8, Shh | 9.1 | 4–18 | [16] |
| IMR90       | Ascl1, Nurr1, Pitx3, Ngn2, Sox2 | R27, Shh, FGF-8, NEAA | 1–2 | 10–20 | [31] |
| bFLJ        | Ascl1, Myt11, Lmx1a, Lmx1b, Foxa2, Otx2 | N2, B7, BDNF, GDNF, NT3, db-cAMP, CHIR99021, SHH, LDN-193189 | N/A | 15 | [32] |
| MEF         | Nurr1; Ascl1 | ITS, N2, B27, ascorbic acid, bFGF, EGF, FGF8b, Shh | 33 | 31 | [33] |
| MEF; TTFs, RHF | Ascl1, Brn2, Myt11, Foxa2, Nurr1 | BDNF, GDNF, db-cAMP, ascorbic acid, N2, bFGF, FGF8, LIF | 3.88; 19.63 | 20 | [34] |
| MEF         | Ascl1, Pitx3, Nurr1, Lmx1a | N2, B2, 27,632, CHIR, VC, DM, SB, Pur, NGF, GDNF, BDNF, TGF83, serum-free | N/A | 10 | [35] |
| MRC5        | Ascl1, Nurr1, Lmx1a, mir124, p53 shRNA | N2, B27, 27,632, CHIR, VC, DM, SB, Pur, NGF, GDNF, BDNF, TGF83, serum-free | 59.2 | 9 | [9] |

Abbreviations: HEF, human embryonic fibroblasts; HPF, human postnatal fibroblasts; MEF, mouse embryonic fibroblasts; IMR90, human fetal fibroblasts; HAF, human adult fibroblasts; TTFs, adult mouse tail tip fibroblasts; bFLJ, human fetal lung fibroblasts; MRC5, human fetal lung fibroblast.
doublecortin+ neuroblasts and neurons in vivo [44]. Using Lmx1a, Neurog2; Ascl1 and/or Dlx2, astrocytes from adult human pigmented epidermal melanocytes can be directly reprogrammed to retinal progenitors and neurons by deletion of p53 [45]. Primary mouse liver cells can be efficiently converted to iDA neurons. The efficiency while DM promotes the survival and maturation of induced cholinergic neurons converted from human fibroblasts by Neurogenin 2 [23]. SHH and FGF8b promote the reprogramming of mouse embryonic fibroblasts into iDA neurons at an efficiency (%) Time (days) Ref. 85.4; 33.7 26; 22 [36,37] 76.8 ± 6.4 10–21 [39] 22–40 – 16 [64] 20–30 – 12–18 [65] 2.5–3.5 20 [40] 20.8 ± 5.9; 6.8 ± 2.9 4–12 weeks [44] 80 5–10 [45] 20.8 ± 2.9 4–12 weeks [44] 13 [43] 19.3 ± 2.9 4–12 weeks [44] 60 of 200 (30%) 6 hrs [59] 80 5–10 [45] 43 ± 7; 91 ± 2 7 [48] 13 [46] 48 28 [55,56] 22 16 [64] 20 20 [55,56] 14 [62] 21 [41] 13.9 ± 3.5 12 [43] 19.3 ± 2.9 4–12 weeks [44] 20.8 ± 2.9 4–12 weeks [44] 13 [46] 19.3 ± 2.9 4–12 weeks [44] 43 ± 7; 91 ± 2 7 [48] 48 28 [55,56] 22 16 [64] 20 20 [55,56] 14 [62] 21 [41] 13.9 ± 3.5 12 [43] 19.3 ± 2.9 4–12 weeks [44] 20.8 ± 2.9 4–12 weeks [44] 13 [46] 19.3 ± 2.9 4–12 weeks [44] 43 ± 7; 91 ± 2 7 [48] 48 28 [55,56] 22 16 [64] 20 20 [55,56] 14 [62] 21 [41] 13.9 ± 3.5 12 [43] 19.3 ± 2.9 4–12 weeks [44] 20.8 ± 2.9 4–12 weeks [44] 13 [46] 19.3 ± 2.9 4–12 weeks [44] 43 ± 7; 91 ± 2 7 [48] 48 28 [55,56] 22 16 [64] 20 20 [55,56] 14 [62] 21 [41] 13.9 ± 3.5 12 [43] 19.3 ± 2.9 4–12 weeks [44] 20.8 ± 2.9 4–12 weeks [44] 13 [46] 19.3 ± 2.9 4–12 weeks [44] 43 ± 7; 91 ± 2 7 [48] 48 28 [55,56] 22 16 [64] 20 20 [55,56] 14 [62] 21 [41] 13.9 ± 3.5 12 [43] 19.3 ± 2.9 4–12 weeks [44] 20.8 ± 2.9 4–12 weeks [44] 13 [46] 19.3 ± 2.9 4–12 weeks [44] 43 ± 7; 91 ± 2 7 [48] 48 28 [55,56] 22 16 [64] 20 20 [55,56] 14 [62] 21 [41] 13.9 ± 3.5 12 [43] 19.3 ± 2.9 4–12 weeks [44] 20.8 ± 2.9 4–12 weeks [44] 13 [46] 19.3 ± 2.9 4–12 weeks [44] 43 ± 7; 91 ± 2 7 [48] 48 28 [55,56] 22 16 [64] 20 20 [55,56] 14 [62] 21 [41]
efficiency of 20% in 7 days with 7 compounds (VPA, CHIR99021, TGFβR-1/ALK5 inhibitor Repsox, forskolin, JNK inhibitor SP600125, PKC inhibitor GO6983 and Y-27632) [27]. In another study, human fibroblasts are efficiently converted to neuronal cells by a cocktail of six compounds (SB-431542, LDN-193189, CHIR99021, PD0325901, Pifithrin-α and Forskolin) [70]. Furthermore, astrocytes are converted to neuronal cells by VPA, CHIR99021 and Repsox [65]. Different types of somatic cells have been converted to neural stem cells, neural progenitor cells or neural crest cells by various combinations of small molecular compounds [63,71–73].

Many studies have shown that hypoxia (5% O2) promotes cellular reprogramming including the direct conversion of various cell types to neurons. For example, the conversion of human fibroblasts by BAM and NeuroD1 to MAP2+ neurons is increased 2.4 folds by hypoxia [74]. Hypoxia promotes the conversion of different somatic cells to neural progenitor cells [63]. Our studies have shown that hypoxia increases the transdifferentiation of human fibroblasts to induced dopaminergic neurons [9] and induced serotonergic neurons [25].

It appears that cell culture conditions, including small molecule compounds, growth factors and hypoxia, impinge on the epigenetic landscape of the genome by activating various signal transduction pathways in the cell. These signaling events, either by themselves, or in conjunction with transcription factors used in reprogramming, must change the epigenome so that the genome is read differently to produce various types of neurons. Understanding the mechanistic details of transdifferentiation will not only reveal fundamental insights into the molecular definition of cell types, but also enable the development of more efficient and useful reprogramming methods.

6. Mechanism of transdifferentiation

The key transcription factor in the direct conversion of fibroblasts to various types of neurons is Ascl1 [10,75]. By itself, Ascl1 reprograms MEF cells to immature neurons, which can mature by coculturing with glia cells. Although Brn2 and Myt11 enhance the efficiency in generating mature neurons, no neuron is produced in the absence of Ascl1 [10,75]. Ascl1, as known as Mash1, belongs to the proneural bHLH gene family, which perform important functions in the induction of various types of neurons. Different types of somatic cells have been converted to neural stem cells, neural progenitor cells or neural crest cells by various combinations of small molecular compounds [63,71–73].

Recent studies have shown the critical role of p53 in the direct conversion of fibroblasts to various types of induced neurons. Depletion of p53 alone converts 70–85% fibroblasts to induced neurons after 3–4 weeks. The addition of Ascl1, Brn2 and Neurod2 greatly increases the conversion, as p53 binds the promoter of Neurod2 and regulates its expression during fibroblast-to-neuron conversion [83]. Depletion of p53 targets p16ink4a or p19arf also reprograms human fibroblasts to induced neurons [84]. Blocking the activity of p53 with a dominant-negative mutant p53 significant improves the conversion of human fibroblasts to IDA neurons by Ascl1, Nurr1 and Lmx1a [85]. We show that p53 attenuation significantly enhances the transdifferentiation of human fibroblasts to IDA neurons by inducing the expression of Tet1, a DNA hydroxylase [9] that oxidizes 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) [86], a DNA modification particularly abundant in neurons [87]. Tet1 is also induced when human fibroblasts are arrested at G1 or upon the expression of reprogramming factors (Ascl1, Nurr1 and Lmx1a). The synergistic induction of Tet1 by p53 knockdown, G1 arrest and expression of reprogramming factors appears to drive the conversion of the epigenome from a fibroblast state to a neuronal state. Overexpression of Tet1 significantly enhances the conversion, whereas Tet1 knockdown during conversion is toxic to the cell [9]. The important role of p53 is corroborated in the direct conversion of human fibroblasts to induced serotonergic neurons by Ascl1, FoxA2, Lmx1b and FEV [25].

Although the conversion of fibroblasts to neurons is driven by Ascl1, transcription factors that specify dopaminergic neurons must be present during conversion in order to generate induced dopaminergic neurons [8,15,16]. Lmx1a is a critical transcription factor in the initial specification of mesodiencephalic DA neurons [88]. In proliferating precursor cells of mesodiencephalic DA neurons, Lmx1a acts as an early activator of the DA differentiation program by inducing the expression of Msx1 [89]. Both of them cooperate to induce Ngn2 and support neuronal differentiation to generate midbrain DA neurons [89]. Overexpression of Lmx1a in embryonic stem cells increases the generation of midbrain DA neurons [89]. Nurr1 is a key transcription factor controlling the terminal differentiation of midbrain DA neurons [90]. Along with Ptx3 and other transcription factors, Nurr1 drives the development of postmitotic DA neurons to mature midbrain DA neurons by helping these neurons acquire their neurotransmitter identity. Nurr1 induces the expression of a battery of genes that determine the identity of midbrain DA neurons, including TH, DAT, VMAT2, AADC, etc. [90]. Nurr1 knockout mice die at birth and lack midbrain DA neurons [91].

Another route for the transdifferentiation of fibroblasts to neurons is through microRNAs, without the need for Ascl1. Initially, miR-124 and miR-9/9* are shown to facilitate the transdifferentiation of human fibroblasts to induced neurons by Ascl1, NeuroD2 and Myt11 [92]. Subsequently, it is found that miR124, Myt11 and Brn2, in the absence of Ascl1, convert human fibroblasts to induced neurons [93]. It appears that miR-124 or miR-9/9* may promote a neuronal fate by regulating the neural progenitor RAG chromatin-remodelling complex. These miRNAs are also implicated in controlling numerous genes that regulate neuronal differentiation and function, such as components of the REST complex including REST and CoREST, and polypryrimidine-tract-biding (PTB) protein [92]. Overexpression of pluripotency stem cell-specific miRNA-302/367 cluster and the neuron-specific miRNAs miRNA-9/9* and miRNA-124 converts human fibroblasts to neurons [94]. Forced expression of such miRNAs [21,22,84,95] or repression of PTB protein [96] reprograms a diverse array of cell types to neurons.

7. IDA neurons for PD research and therapy

There are three unmet needs in Parkinson’s disease: finding a predicative biomarker, elucidating disease mechanism, and discovering a disease-modifying therapy. Patient-specific IDA neurons and iPSC-derived DA neurons are highly valuable in meeting these challenges. While iPSCs provide a permanent and replenishable resource to generate patient-specific midbrain DA neurons, their drawbacks are the long time required to differentiate iPSCs to mature midbrain DA neurons [97] and the resetting of epigenetic information during reprogramming [98]. The differentiation process reestablishes the epigenetic information to that of embryonic DA neurons, which are useful to study the intrinsic, genetically-determined vulnerabilities important to PD. But it might miss the epigenetic information imparted by age. In contrast, the transdifferentiation of human fibroblasts to IDA neurons...
neurons preserves the epigenetic information associated with the age of the fibroblasts [99]. The added benefit is that transdifferentiation is much faster, taking a few days to see neurons and about 30 days to generate iDA neurons with mature synaptic physiology [9]. Thus, iDA neurons are a very useful addition to the toolset in using PD patients to study Parkinson’s disease, considering the pros and cons of iDA neurons and iPSC-derived DA neurons (Table 3). For example, patient-specific iDA neurons can be generated from a large number of PD patients and normal subjects for biomarker discovery. These iDA neurons share many properties similar to nigral DA neurons in the brain of the subjects, including sophisticated regulation of dopaminergic transmission, such as the regulation of dopamine release by autoreceptors [9]. The patient-specific iDA neurons would thus be a very close surrogate for prototypic and transcriptomic studies that may identify a molecular signature for idiopathic Parkinson’s disease, which so far has defined invasive experimental analyses. Mechanistic studies on PD can also significantly benefit from patient-specific iDA neurons, because it is much easier for more researchers to adopt the highly efficient transdifferentiation protocols to generate patient-specific DA neurons, as compared to the more challenging technical requirement for the differentiation of iPSCs to midbrain DA neurons.

Perhaps the most anticipated development for iDA neurons is to test its potentials in cell replacement therapy of Parkinson’s disease. Transplantation of mouse iDA neurons in 6-OHDA-lesioned mice restores locomotor deficits [16]. Similarly, mouse iDA neurons transplanted in 6-OHDA-lesioned rats functionally integrate into the rat neuronal network and alleviate motor symptoms [100]. Further studies are needed to evaluate human iDA neurons grafted in animal PD models. The key questions are whether iDA neurons can survive in animal brain, integrate with existing neuronal network, extend significant axon arbor and reduce locomotor deficits. It has taken many years of intensive efforts to develop effective methods to transplant human pluripotent stem cell-derived midbrain DA neurons for cell replacement therapy of Parkinson’s disease. We are still at a very early stage in the development of iDA neurons for transplantation studies. There are signs that this new tool can be very useful. First, the direct conversion does not involve any stem cell intermediates, which means less worries for mitotic cells that can potentially be tumorigenic. Indeed, our study has shown that 93% of the cells at day 10 are neurons (including 59% that are TH+). The remaining 7% cells that are indeed factors, Nature 476 (7359) (2011) 220–227.

Second, the use of fibroblasts obviates ethical concerns associated with fetal tissue or embryonic stem cells. Third, the ease to generate iDA neurons from any subject makes autologous transplantation more feasible. The disadvantage of using iDA neurons for cell replacement studies include the difficulty to significantly expand dermal fibroblasts as the starting material; the epigenetic memory of the age of the fibroblasts; and potential DNA damage in dermal fibroblasts in patient of advanced age. Future development is needed for a footprint-free system to reliably convert human dermal fibroblasts to iDA neurons at a high efficiency. The current system, in which viral transgenes are integrated in the iDA neurons, is unlikely to be suitable for clinical applications.

8. Conclusion

The explosive growth in cell reprogramming in the past ten years since the discovery of mouse iPScs has fundamentally transformed biomedical research. With the ability to convert easily accessible cells, such as skin fibroblasts, to inaccessible cells that are lost in diseases (e.g. midbrain DA neurons in PD), it is possible to generate cells in vitro that are increasingly similar to their in vivo counterparts. Although there are still many questions on iDA neurons, the ability of this technology to capture the intrinsic properties of nigral DA neurons in PD patients will lead to useful applications that will address the three unmet needs for Parkinson’s disease, with the ultimate goal of finding a disease-modifying therapy (Fig. 1).

Acknowledgement

The work was supported by the Department of Veterans Affairs Merit Award I01BX002452, NYSTEM contracts C028129, C029536 and C026714, SUNY REACH, National Program of Basic Research Fund of China [grant numbers 2010CB945200, 2011CB504104] and National Natural Science Fund [grant numbers 81430022, 81371407, 91332107].

References

1. A. Lang, A. Lozano, Medical progress: Parkinson’s disease (first of two parts), N. Engl. J. Med. 339 (1998) 1044–1053.
2. A. Lange, A. Lozano, Parkinson’s disease: second of two parts, N. Engl. J. Med 339 (1998) 1130–1143.
3. J. Hardy, Genetic analysis of pathways to Parkinson disease, Neuron 68 (2) (2010) 201–206.
4. Z. Kefalopoulos, et al., Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports, JAMA Neurol. 71 (1) (2014) 83–87.
5. R.A. Barker, et al., Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson’s disease, Lancet Neurol. 12 (1) (2013) 84–91.
6. R.A. Barker, J. Dronin-Ouellet, M. Parmar, Cell-based therapies for Parkinson disease (midash) past insights and future potential, Nat. Rev. Neurosci. 11 (9) (2015) 492–503.
7. S. Grešíl, et al., Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson’s disease, Cell Stem Cell 15 (5) (2014) 653–665.
8. M. Ciaizz, et al., Direct generation of functional dopaminergic neurons from mouse and human fibroblasts, Nature 476 (7359) (2011) 224–227.
9. H. Jiang, et al., Cell cycle and p53 gate the direct conversion of human fibroblasts to dopaminergic neurons, Nat. Commun. 6 (2015) 10100.
10. T. Vierbuchen, et al., Direct conversion of fibroblasts to functional neurons by defined factors, Nature 463 (7284) (2010) 1035–1041.
11. Z.P. Pang, et al., Induction of human neuronal cells by defined transcription factors, Nature 476 (7359) (2011) 220–223.
12. Z. Zhou, et al., Reprogramming non-human primate somatic cells into functional neuronal cells by defined factors, Mol. Brain 7 (1) (2014) 1–11.
13. F. Mirakhorai, et al., Direct conversion of human fibroblasts into dopaminergic neural progenitor-like cells using TAT-mediated protein transduction of recombi-
[91] R.H. Zetterstrom, et al., Dopamine neuron agenesis in Nurr1-deficient mice, Science 276 (5310) (1997) 248–250.
[92] A.S. Yoo, et al., MicroRNA-mediated conversion of human fibroblasts to neurons, Nature 476 (7359) (2011) 228–231.
[93] R. Ambasudhan, et al., Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions, Cell stem Cell 9 (2) (2011) 113–118.
[94] C. Zhou, et al., MicroRNA 302/367 cluster effectively facilitates direct reprogramming from human fibroblasts into functional neurons, Stem Cells Dev. 24 (23) (2015) 2746–2755.
[95] S. Lau, et al., Direct neural conversion from human fibroblasts using self-regulating and nonintegrating viral vectors, Cell Rep. 9 (5) (2014) 1673–1680.
[96] Y. Xue, et al., Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated MicroRNA circuits, Cell (2013).
[97] H. Jiang, et al., Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells, Nat. Commun. 3 (2012) 668.
[98] R.A. Young, Control of the embryonic stem cell state, Cell 144 (6) (2011) 940–954.
[99] J. Mertens, et al., Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects, Cell Stem Cell 17 (6) (2015) 705–718.
[100] M.T. Dell’Anno, et al., Remote control of induced dopaminergic neurons in parkinsonian rats, J. Clin. Investig. 124 (7) (2014) 3215–3229.